Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Mar 2009

Wagner Lars M, Villablanca Judith G, Stewart Clinton F, Crews Kristine R, Groshen Susan, Reynolds C Patrick, Park Julie R, Maris John M, Hawkins Randall A, Daldrup-Link Heike E, Jackson Hollie A, Matthay Katherine K

Abstract excerpt

PURPOSE: Irinotecan and temozolomide have single-agent activity and schedule-dependent synergy against neuroblastoma. Because protracted administration of intravenous irinotecan is costly and inconvenient, we sought to determine the maximum-tolerated dose (MTD) of oral irinotecan combined with temozolomide in children with recurrent/resistant high-risk neuroblastoma. PATIENTS AND METHODS: Patients received oral...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Camptothecin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dacarbazine

Share to Glucuronosyltransferase

Share to Irinotecan

Share to Maximum Tolerated Dose

Share to Neuroblastoma

Share to Temozolomide

Source

Open in PubMed Open full text

Identifiers

PMID: 19171709
DOI: 10.1200/JCO.2008.18.5918
PMCID: PMC2667827

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study.PMID 19171709Read ↗

Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors.Semantic proximity Read ↗

Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.Semantic proximity Read ↗

Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin (IREC) for refractory or relapsed neuroblastomaSemantic proximity Read ↗

Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children’s Oncology Group Study ANBL0531Semantic proximity Read ↗

A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high‐risk neuroblastomaSemantic proximity Read ↗

Reducing irinotecan-associated diarrhea in children.Semantic proximity Read ↗

Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children's oncology group study.Semantic proximity Read ↗

Relationship Between Topotecan Systemic Exposure and Tumor Response in Human Neuroblastoma XenograftsSemantic proximity Read ↗

Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trialSemantic proximity Read ↗

Outcome after Reduced Chemotherapy for Intermediate-Risk NeuroblastomaSemantic proximity Read ↗

Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcomaSemantic proximity Read ↗

Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.